INTELLIA THERAPEUTICS ($NTLA) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$1.10 per share, beating estimates of -$1.31 by $0.21. The company also reported revenue of $16,629,999, beating estimates of $12,111,367 by $4,518,632.
You can see Quiver Quantitative's $NTLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INTELLIA THERAPEUTICS Insider Trading Activity
INTELLIA THERAPEUTICS insiders have traded $NTLA stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- JOHN M LEONARD (President and CEO) sold 26,807 shares for an estimated $326,509
- DAVID LEBWOHL (EVP, Chief Medical Officer) sold 9,557 shares for an estimated $116,404
- LAURA SEPP-LORENZINO (EVP, Chief Scientific Officer) sold 8,966 shares for an estimated $109,205
- JAMES BASTA (EVP, General Counsel) sold 7,074 shares for an estimated $86,161
- DEREK HICKS (EVP, Chief Business Officer) sold 6,502 shares for an estimated $79,194
- MICHAEL P DUBE (VP, Chief Accounting Officer) sold 1,372 shares for an estimated $16,710
- ELIANA CLARK (EVP, Chief Technical Officer) sold 679 shares for an estimated $6,104
- MUNA BHANJI has made 0 purchases and 2 sales selling 530 shares for an estimated $4,894.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INTELLIA THERAPEUTICS Hedge Fund Activity
We have seen 172 institutional investors add shares of INTELLIA THERAPEUTICS stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP removed 4,950,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $57,717,000
- ALLIANCEBERNSTEIN L.P. removed 1,928,469 shares (-87.9%) from their portfolio in Q4 2024, for an estimated $22,485,948
- BALYASNY ASSET MANAGEMENT L.P. added 1,556,433 shares (+207.6%) to their portfolio in Q4 2024, for an estimated $18,148,008
- CITADEL ADVISORS LLC added 1,504,631 shares (+152.1%) to their portfolio in Q4 2024, for an estimated $17,543,997
- UBS GROUP AG added 1,463,336 shares (+525.6%) to their portfolio in Q4 2024, for an estimated $17,062,497
- PICTET ASSET MANAGEMENT HOLDING SA removed 1,394,911 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $16,264,662
- MORGAN STANLEY added 1,238,512 shares (+48.1%) to their portfolio in Q4 2024, for an estimated $14,441,049
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INTELLIA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $NTLA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 03/05/2025
- Oppenheimer issued a "Outperform" rating on 11/11/2024
To track analyst ratings and price targets for INTELLIA THERAPEUTICS, check out Quiver Quantitative's $NTLA forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
